Literature DB >> 28924413

Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity.

Kelly M Bui1, SriniVas R Sadda1,2, Hani Salehi-Had3.   

Abstract

Deferoxamine is a commonly used chelating agent for secondary hemochromatosis. We report a rare retinal manifestation of deferoxamine toxicity in a 68-year-old man and provide supporting multimodal imaging and electrophysiology. The patient had iron overload related to transfusion-dependent myelodysplastic syndrome and developed a pseudovitelliform macular lesion related to deferoxamine toxicity. We also describe for the first time the worsening of this maculopathy on deferasirox, an alternative chelating agent. Macular pseudovitelliform lesion is a unique manifestation of deferoxamine toxicity that can be mistaken for pattern dystrophy. It is important to recognize this manifestation, because discontinuation of the offending agent may halt or reverse the toxicity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28924413      PMCID: PMC5596954          DOI: 10.5693/djo.02.2016.12.001

Source DB:  PubMed          Journal:  Digit J Ophthalmol        ISSN: 1542-8958


  11 in total

1.  Macular vitelliform lesion in desferrioxamine-related retinopathy.

Authors:  Mohamed A Genead; Gerald A Fishman; Anastasios Anastasakis; Martin Lindeman
Journal:  Doc Ophthalmol       Date:  2010-06-09       Impact factor: 2.379

2.  Bilateral vitelliform maculopathy and deferoxamine toxicity.

Authors:  Christine R Gonzales; Albert P Lin; Robert E Engstrom; Allan E Kreiger
Journal:  Retina       Date:  2004-06       Impact factor: 4.256

3.  Ocular toxicity of desferrioxamine--an example of copper promoted auto-oxidative damage?

Authors:  H Pall; D R Blake; P Winyard; J Lunec; A Williams; P A Good; E E Kritzinger; A Cornish; R C Hider
Journal:  Br J Ophthalmol       Date:  1989-01       Impact factor: 4.638

4.  Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38.

Authors:  Alexa Klettner; Stefan Koinzer; Vicki Waetzig; Thomas Herdegen; Johann Roider
Journal:  Cutan Ocul Toxicol       Date:  2010-06       Impact factor: 1.820

5.  Efficacy of brinzolamide ophthalmic suspension 1% for treatment of a vitelliform macular lesion in a patient with desferrioxamine retinopathy.

Authors:  Mohamed A Genead; Gerald A Fishman
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2011-12-08

6.  The expanded clinical spectrum of deferoxamine retinopathy.

Authors:  Robert Haimovici; Donald J D'Amico; Evangelos S Gragoudas; Samuel Sokol
Journal:  Ophthalmology       Date:  2002-01       Impact factor: 12.079

7.  Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.

Authors:  J B Porter; M S Jaswon; E R Huehns; C A East; J W Hazell
Journal:  Br J Haematol       Date:  1989-11       Impact factor: 6.998

8.  Multiple transfused thalassemia major: ocular manifestations in a hospital-based population.

Authors:  Rashi Taneja; Pankaj Malik; Mamta Sharma; Mahesh C Agarwal
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

9.  Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.

Authors:  N F Olivieri; J R Buncic; E Chew; T Gallant; R V Harrison; N Keenan; W Logan; D Mitchell; G Ricci; B Skarf
Journal:  N Engl J Med       Date:  1986-04-03       Impact factor: 91.245

10.  Multimodal imaging in deferoxamine retinopathy.

Authors:  Francesco Viola; Giulio Barteselli; Laura DellʼArti; Diego Vezzola; Chiara Mapelli; Edoardo Villani; Roberto Ratiglia
Journal:  Retina       Date:  2014-07       Impact factor: 4.256

View more
  2 in total

1.  Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature.

Authors:  Constantine D Georgakopoulos; Foteini Tsapardoni; Elli V Kostopoulou; Olga E Makri
Journal:  BMC Ophthalmol       Date:  2018-09-12       Impact factor: 2.209

Review 2.  [Maculopathy in sickle cell disease].

Authors:  Isabel Bachmeier; Christiane Blecha; Jürgen Föll; Daniel Wolff; Herbert Jägle
Journal:  Ophthalmologe       Date:  2021-01-27       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.